Policy & Regulation
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
10 December 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Tuesday that that the first participant has been dosed in the Phase 1 clinical trial of IBI3011, a...
D3 Bio completes USD108m Series B financing round
10 December 2025 - D3 Bio, a China-based global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, announced on Tuesday that it has comp...
Hemab Therapeutics announces positive Phase 2 multiple ascending dose study results for sutacimig
9 December 2025 - Denmark-based clinical-stage biotechnology company Hemab Therapeutics on Monday reported positive results from the completed Phase 2 multiple ascending dose (MAD) portion of its CL-1...
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
9 December 2025 - Cereno Scientific (Nasdaq First North: CRNO B), a Swedish biotech company developing treatments for rare cardiovascular and pulmonary diseases, announced on Monday that it has receiv...
Champions Oncology expands bioanalytical services with new technology and leadership
8 December 2025 - Champions Oncology Inc (NASDAQ:CSBR), a technology-enabled oncology research organisation, announced on Monday that it has expanded its clinical bioanalytical services with the integ...
Mirum Pharmaceuticals to acquire Bluejay Therapeutics for HDV treatment
8 December 2025 - Rare disease company Mirum Pharmaceuticals Inc (Nasdaq:MIRM) on Monday announced a definitive agreement to acquire Bluejay Therapeutics, a privately held biotechnology company focuse...